{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T10:56:12Z","timestamp":1777632972619,"version":"3.51.4"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,29]]},"DOI":"10.7759\/cureus.85064","type":"journal-article","created":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T06:00:13Z","timestamp":1748584813000},"source":"Crossref","is-referenced-by-count":1,"title":["Sublingual Crushed Levodopa for Parkinson\u2019s Disease Management of a Lewy Body Dementia Patient With Dysphagia: A Case Report"],"prefix":"10.7759","author":[{"given":"Kristin","family":"Regehr","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fiona","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reema","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony","family":"Lau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1212\/CON.0000000000001496","article-title":"Lewy body dementia","volume":"30","author":"Galvin JE","year":"2024","unstructured":"Galvin JE. Lewy body dementia. Continuum (Minneap Minn). 2024, 30:1673-98. 10.1212\/CON.0000000000001496","journal-title":"Continuum (Minneap Minn)"},{"key":"ref2","unstructured":"AbbVie Corporation. LEVODOPA product monograph. (2022). Accessed: January 23, 2025: https:\/\/pdf.hres.ca\/dpd_pm\/00064444.PDF."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s00455-015-9671-9","article-title":"Dysphagia in Parkinson's disease","volume":"31","author":"Suttrup I","year":"2016","unstructured":"Suttrup I, Warnecke T. Dysphagia in Parkinson's disease. Dysphagia. 2016, 31:24-32. 10.1007\/s00455-015-9671-9","journal-title":"Dysphagia"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.31.2.215","article-title":"Absorption of levodopa after rectal administration","volume":"31","author":"Eisler T","year":"1981","unstructured":"Eisler T, Eng N, Plotkin C, Calne DB. Absorption of levodopa after rectal administration. Neurology. 1981, 31:215-7. 10.1212\/wnl.31.2.215","journal-title":"Neurology"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1159\/000441489","article-title":"Effect of rectal levodopa administration: a case report","volume":"7","author":"Vogelzang JM","year":"2015","unstructured":"Vogelzang JM, Luinstra M, Rutgers AW. Effect of rectal levodopa administration: a case report. Case Rep Neurol. 2015, 7:209-12. 10.1159\/000441489","journal-title":"Case Rep Neurol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.01196","article-title":"Physiological and pharmaceutical considerations for rectal drug formulations","volume":"10","author":"Hua S","year":"2019","unstructured":"Hua S. Physiological and pharmaceutical considerations for rectal drug formulations. Front Pharmacol. 2019, 10:1196. 10.3389\/fphar.2019.01196","journal-title":"Front Pharmacol"},{"key":"ref7","article-title":"Case report: successful use of rectally administered levodopa-carbidopa","volume":"47","author":"Cooper SD","year":"2001","unstructured":"Cooper SD, Ismail HA, Frank C. Case report: successful use of rectally administered levodopa-carbidopa. Can Fam Physician. 2001, 47:112-3.","journal-title":"Can Fam Physician"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1177\/08971900221151194","article-title":"A review of levodopa formulations for the treatment of Parkinson's disease available in the United States","volume":"37","author":"Livingston C","year":"2024","unstructured":"Livingston C, Monroe-Duprey L. A review of levodopa formulations for the treatment of Parkinson's disease available in the United States. J Pharm Pract. 2024, 37:485-94. 10.1177\/08971900221151194","journal-title":"J Pharm Pract"},{"key":"ref9","article-title":"Considerations in developing sublingual tablets\u2014an overview","volume":"38","author":"Sayeed V","year":"2014","unstructured":"Sayeed V, Ashraf M. Considerations in developing sublingual tablets\u2014an overview. Pharm Tech. 2014, 38:11.","journal-title":"Pharm Tech"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.4103\/ija.IJA_178_17","article-title":"Perioperative sublingual levodopa in Parkisnon's Disease: a useful alternative!","volume":"61","author":"Bhirud PH","year":"2017","unstructured":"Bhirud PH, Kate JA. Perioperative sublingual levodopa in Parkisnon's Disease: a useful alternative!. Indian J Anaesth. 2017, 61:432-4. 10.4103\/ija.IJA_178_17","journal-title":"Indian J Anaesth"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1615\/critrevtherdrugcarriersyst.v25.i5.20","article-title":"Sublingual drug delivery","volume":"25","author":"Goswami T","year":"2008","unstructured":"Goswami T, Jasti B, Li X. Sublingual drug delivery. Crit Rev Ther Drug Carrier Syst. 2008, 25:449-84. 10.1615\/critrevtherdrugcarriersyst.v25.i5.20","journal-title":"Crit Rev Ther Drug Carrier Syst"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.36.6.739","article-title":"Levodopa pharmacokinetics and pharmacodynamics in fluctuating Parkinsonian patients","volume":"36","author":"Nutt JG","year":"1986","unstructured":"Nutt JG, Woodward WR. Levodopa pharmacokinetics and pharmacodynamics in fluctuating Parkinsonian patients. Neurology. 1986, 36:739-44. 10.1212\/wnl.36.6.739","journal-title":"Neurology"},{"key":"ref13","unstructured":"Levodopa - drug profile. PubChem, National Center for Biotechnology Information. (2025). Accessed. May 1, 2025: https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/6047."},{"key":"ref14","unstructured":"Levodopa - chemical and physical properties. ChemicalBook. (2023). Accessed. May 1, 2025: https:\/\/www.chemicalbook.com\/ProductMSDSDetailCB2402938_EN.htm."},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.01328","article-title":"Advances in nanoparticulate drug delivery approaches for sublingual and buccal administration","volume":"10","author":"Hua S","year":"2019","unstructured":"Hua S. Advances in nanoparticulate drug delivery approaches for sublingual and buccal administration. Front Pharmacol. 2019, 10:1328. 10.3389\/fphar.2019.01328","journal-title":"Front Pharmacol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1002\/jps.2600540323","article-title":"Preparation and stability of glyceryl trinitrate sublingual tablets prepared by direct compression","volume":"54","author":"RI MD","year":"1965","unstructured":"RI MD, FO CD, SH RF. Preparation and stability of glyceryl trinitrate sublingual tablets prepared by direct compression. J Pharm Sci. 1965, 54:447-51. 10.1002\/jps.2600540323","journal-title":"J Pharm Sci"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3390\/separations9080224","article-title":"An overview of methods for L-dopa extraction and analytical determination in plant matrices","volume":"9","author":"Tesoro C","year":"2022","unstructured":"Tesoro C, Lelario F, Ciriello R, Bianco G, Di Capua A. An overview of methods for L-dopa extraction and analytical determination in plant matrices. Separations. 2022, 9:224. 10.3390\/separations9080224","journal-title":"Separations"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2024.106819","article-title":"Can membrane permeability of zwitterionic compounds be predicted by the solubility-diffusion model?","volume":"199","author":"Ebert A","year":"2024","unstructured":"Ebert A, Dahley C. Can membrane permeability of zwitterionic compounds be predicted by the solubility-diffusion model?. Eur J Pharm Sci. 2024, 199:106819. 10.1016\/j.ejps.2024.106819","journal-title":"Eur J Pharm Sci"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(98)90152-7","article-title":"Concentration-response relationship of levodopa in patients at different stages of Parkinson's disease","volume":"64","author":"Harder S","year":"1998","unstructured":"Harder S, Baas H. Concentration-response relationship of levodopa in patients at different stages of Parkinson's disease. Clin Pharmacol Ther. 1998, 64:183-91. 10.1016\/S0009-9236(98)90152-7","journal-title":"Clin Pharmacol Ther"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/368636-sublingual-crushed-levodopa-for-parkinsons-disease-management-of-a-lewy-body-dementia-patient-with-dysphagia-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T06:00:15Z","timestamp":1748584815000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/368636-sublingual-crushed-levodopa-for-parkinsons-disease-management-of-a-lewy-body-dementia-patient-with-dysphagia-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,29]]},"references-count":19,"URL":"https:\/\/doi.org\/10.7759\/cureus.85064","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5,29]]}}}